ASCO 2026 | DXC006, a CD56-targeting antibody-drug conjugate, in advanced solid tumors
Hongyun Zhao, MD, Sun Yat-Sen University Cancer Center, Guangzhou, China, discusses first-in-human Phase I dose-escalation findings (NCT06224855) evaluating DXC006, a novel CD56-targeting antibody-drug conjugate, in patients with advanced solid tumors. Results demonstrated a manageable safety profile with no dose-limiting toxicities observed, alongside encouraging antitumor activity across multiple tumor types, with particularly notable objective response and disease control rates in small cell lung cancer (SCLC) and neuroendocrine neoplasms. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Today we are presenting the results, preliminary results from the phase 1 study of DXC006. It’s a first-in-class CD56 ADC. So the promising efficacy data includes the efficacy and toxicity. In the efficacy data, we found that in the more than second-line small cell lung cancer, the ORR was 59%. And for the lung endocrine tumor, the ORR was 45%. And for second-line extensive-stage small cell lung cancer, the ORR was as high as 75%...
Today we are presenting the results, preliminary results from the phase 1 study of DXC006. It’s a first-in-class CD56 ADC. So the promising efficacy data includes the efficacy and toxicity. In the efficacy data, we found that in the more than second-line small cell lung cancer, the ORR was 59%. And for the lung endocrine tumor, the ORR was 45%. And for second-line extensive-stage small cell lung cancer, the ORR was as high as 75%. For the neuroendocrine tumor, more than second line, the ORR was 21%. So we think this efficacy data was very promising. And for talking about the toxicity, the grade 3 and above TRAEs were observed in 27 patient patients. It’s lower than other ADC products. And so the CD56 on-target toxicity, such as peripheral neuropathy, were observed in 36 patient patients but most of them are grade one or two. So the grade three and above this kind of toxicity were only observed in three patient patients. So this drug is totally manageable, we are tolerated.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
